Ignite Creation Date:
2024-05-06 @ 7:58 PM
Last Modification Date:
2024-10-26 @ 3:18 PM
Study NCT ID:
NCT06206642
Status:
COMPLETED
Last Update Posted:
2024-01-16
First Post:
2024-01-04
Brief Title:
Comparing 18F-FAPI-04 and 18F-FDG PETCT in Cancer Detection
Sponsor:
The Second Hospital of Lanzhou University
Organization:
The Second Hospital of Lanzhou University
Study Overview
Official Title:
Evaluation of a Novel Targeted Molecular Probe 18F-FAPI-04 PETCT for Various Malignant Tumors Comparison With 18F-FDG PETCT
Status:
COMPLETED
Status Verified Date:
2024-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Evaluating fluoro-18-fibroblast activation protein inhibitor-04 positron emission computed tomographys diagnostic efficacy for primary malignancies versus 18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose
Detailed Description:
In recent years radionuclide labeled fibroblast activating protein inhibitors FAPIs have gradually become a new strategy for targeted diagnosis and therapy In this study radionuclide 18F was used to label FAPI and the imaging value of FAPI was compared with that of common developer 18F-FDG To evaluate the diagnostic value of 18F-FAPI-04 PETCT in various malignant tumors
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None